TREMFYA

Product Overview

About TREMFYA

TREMFYA is a prescription medication used to treat moderate to severe plaque psoriasis in adults. It contains the active ingredient guselkumab, a human interleukin-23 (IL-23) inhibitor.

Key Benefits & Uses

• Treatment of moderate to severe plaque psoriasis in adults
• Reduction of symptoms and improvement of physical appearance of psoriasis-affected skin
• Long-term management of psoriasis with minimal side effects

Active Ingredient & Action

Guselkumab, the active ingredient in TREMFYA, works by binding to the p19 subunit of IL-23, a protein involved in the inflammatory response. By inhibiting IL-23, guselkumab reduces inflammation and slows down the growth of skin cells, leading to improved symptoms and appearance of psoriasis-affected skin.

Important Notes

TREMFYA is administered via subcutaneous injection every 8 weeks. It is essential to follow the recommended dosing schedule and consult with a healthcare professional before starting treatment. Common side effects may include injection site reactions, upper respiratory tract infections, and fatigue. Patients with a history of inflammatory bowel disease or other immune system disorders should use TREMFYA with caution and under close medical supervision.